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ABSTRACT 
Objectives: The aim of this research is to investigate the better biological activities from Rilpivirine analogues based on their Quantitative 
Structure-Property Relationship (QSPR) and pharmacophore study.  
Methods: In this study, we had designed six Rilpivirine analogues. The complementary aided-computational drug design and molecular docking 
was employed to find the best lead candidate. The drug-likeness properties of Rilpivirine analogues were defined by following the Rule of Five.  
Results: The drug-likeness properties of Rilpivirine derivatives (RVN 1-6) were defined by the Rule of Five (RO5), which RVN3 compound showed 
the best RO5 score among others. However, the log P value of RVN1 and RVN4 are lower than 5, while RVN2, RVN3, RVN5 and RVN6 have log P 
values greater than 5. Based on the solubility, RVN1 and RVN4 compounds are more soluble than other analogues including Rilpivirine prototype 
(RVN). The topological polar surface area (TPSA) score of RVN1 and RVN4 showed greater scores compared to others. On the other hand, the TPSA 
score of all Rilpivirine analogues are below 140 Å2. The absorption, distribution, metabolism, and excretion (ADME) properties of Rilpivirine 
analogues were determined, according to blood brain barrier penetration were found within the range of-1.2 to-2.2, which RVN4 showed the lowest 
value compared to others, while RVN showed the highest value. The percentage of human intestinal absorption was observed 100% to all 
compounds. The plasma protein binding percentages was obtained within the range 99.03-99.57%. Moreover, the hydrogen bond donor 
contribution of all compounds was in the range 2-4 bonds, while the acceptor hydrogen bond was found 6 bonds from all compounds. The 
mutagenicity properties showed all compounds could cause mutagenic effect in long-term administration. The carcinogenicity tests were done in 
mouse showed positive results to all compounds, while carcinogenicity test in rat showed negative results upon all compound, except RVN3 which 
gave positive result. From molecular docking result, RVN 1 and RVN 4 showed higher potential inhibition activities to Reverse Transcriptase Human 
Immunodeficiency Virus Type 1 (HIV-1 RT) compared other analogues. 
Conclusion: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have a great potential inhibition against HIV-1 RT. From high throughput 
computational approach, we suggested that RVN 1 and RVN 4 are the potential drug candidates which have better activity among other Rilpivirine 
derivatives. 
Keywords: NNRTIs, Rilpivirine analogues, HIV-1 RT, QSPR, Molecular docking. 
 
INTRODUCTION 
Reverse transcriptase (RT) of the Human Immunodeficiency Virus 
Type 1 (HIV-1) is an enzyme which has the critical role to viral 
replication in the infected host cell. HIV-1 RT consists of two 
subunits, p66 (66 kDa) subunit and p51 (51 kDa) subunit. The p66 
subunit of HIV-1 RT acts two main roles: as DNA polymerase that 
reverse transcripts the single strand of RNA into the double strand 
of DNA, and as an endonucleolytic ribonuclease H (RNase H) that 
degrades the RNA from hybrid DNA. The p51 subunit of RT has only 
structural function. Based on its substantial role in the HIV-1 life-
cycle, RT becomes a primary target for anti-HIV-1 agents. 
To date, the anti-HIV-1 drugs against HIV-1 RT are progressively 
developed. The Non-Nucleoside Reverse Transcriptase Inhibitors 
(NNRTIs) are known as antiretroviral drugs inhibit the HIV-1 
infection. NNRTIs are chemically different from the common 
nucleosides which are not involved in the intracellular metabolism 
for its activity. In general, NNRTIs are a group of small hydrophobic 
compounds (less than 600 Da) with various structure forms that 
particularly inhibit HIV-1.  
NNRTI derivatives can be broadly categorized into first-and second-
generation compounds [1]. The first generation NNRTIs, such as 
nevirapine, delavirdine, TIBO, and loviride (α-anilino-
phenylacetamido (α-APA)), were mainly discovered by random 
screening and are associated with the rapid development of drug 
resistance mutations. The second generation NNRTIs, which 
including efavirenz, the quinoxaline talviraline (HBY-097), the 
Imidazole Capravirine, and Rilpivirine (TMC278) were developed as 
a result of comprehensive strategies involving molecular modeling, 
rationale-based drug synthesis and biological and pharmacokinetic 
evaluations. Second generation NNRTIs tend to be more potent than 
the first generation compounds, and in general are more active 
against a broader spectrum of drug-resistant strains of HIV-1 [1-4]. 
Rilpivirine (diarylpyrimidine, DPAY, trade name: Edurant) is a Non 
Nucleoside Reverse Transcriptase Inhibitor (NNRTI) which is 
approved for treatment of HIV-1 infection in antiretroviral-naive adult 
patients [5, 6]. Rilpivirine acts at the hydrophobic position near the 
NNRTI-binding site, resulting inactivation of the HIV-1 RT and 
terminating the HPV DNA synthesis [7]. Rilpivirine was selected for 
further study due to this compound is able to bind and inhibit the wild 
type of HIV-1 RT and a number of clinically relevant NNRTI-resistant 
variants. This ability derives from the geometrical flexibility of the 
compound within the HIV-1 RT binding pocket [8]. Further 
investigation of the Rilpivirine remains crucial role due to their activity 
against a wide range of drug-resistant variants, therefore it plays an 
important highly active antiretroviral therapy (HARRT) [9]. 
In our study, we utilize high throughput computational approach to 
design and analyze Rilpivirine analogues to overcome the rapid 
emergence of different type strain mutations which lead drug 
resistant by HIV-1 RT. 
MATERIALS AND METHODS 
Protein structure preparation 
The 3D crystal structure of RT-Rilpivirine complex was extracted 
from Protein Data Bank (PDB ID 2ZD1). Subunit p66 was used in this 
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experiment due to this subunit has a crucial role in binding to 
Rilpivirine. Subunit p51 and Rilpivirine molecule were removed 
from the structure. The structure of protein p66 was checked by 
using Procheck to validate its refined structural conformation. 
Ramachandran plot was used to analyze the allowed dihedral phi 
and psi rotations of the protein backbones [10].  
Rilpivirine derivatives designed by quantitative structure–
property relationship (QSPR) 
There are six molecules of Rilpivirine analogues were designed by 
substituting the–R1 and–R2 positions from both side chains of 
Rilpivirine. These molecules are: RV1, RV2, RV3, RV4, RV5 and RV6, 
respectively. The molecule structures are depicted in fig. 1. The 
structures were scored based on their physicochemical properties 
under Molsoft Drug-Likeness platform [11-14]. These physico-
chemical properties are important for developing the drug candidate 
in every stage from design to pre-clinical study. The good lead 
candidates usually have higher values from the parental compound; 
nevertheless the analogue compounds could have similar drug 
likeness value as parental compound.  
Adsorbtion, Distribution, Metabolism, Excretion and toxicity 
(ADMET) analysis 
The ADMET properties of the drug should be highly considered in 
drug development. The early stage of ADMET identification will 
further carry the compound in drug screening. The undesirable 
ADMET properties of the compound will lead major failure in drug 
development. The ADMET prediction of drug candidates used 
ACD/I-lab (ACD/Structure Elucidator 2014) and FAF-Drugs2, which 
consists of compound bioavailability, blood brain penetration, 
human intestinal absorption, and percentage of plasma binding 
protein evaluation [15]. Lazar tool is used to determine toxicity 
prediction toward the living cell [16].  
Molecular docking of RT-Rilpivirine analogues 
The 3D HIV-1 RT was generated from PDB by maintaining the 
interface region and removing the subunit p51, ligand and water 
molecules using Chimera 1.8.1. All 3D Rilpivirine derivative 
structures were generated by Chem Draw Ultra 12.0 for the 
molecular docking experiments and their conformational energy 
were minimized by using MMFF94 force field. The final protein and 
ligand coordinates were saved as pdb files. 
Molecular docking experiment is performed using Autodock Vina 
program (Vina, The Scripps Institute) [17]. The Autodock Tools is 
used to add partial charges by using Gasteiger method and to 
arrange the polar hydrogens in the protein. The ligand is set to have 
flexible torsion angles at all rotatable bonds, while the protein is 
prepared as a rigid structure. Both protein and ligand are s--aved as 
output pdbqt files. For specific docking of ligand rilpirivine 
derivatives onto the HIV-1 RT subunit p66, the grid box volume was 
adjusted to 28x28×28 Å in the x, y and z axes, respectively, with grid-
sizes have a space within 0.450-0.835 Å. The binding energy values 
were calculated based on the total intermolecular energies (kj/mol) 
including hydrogen bond energy, Van Der Wall’s energy, desolvation 
energy and electrostatic energy. On the other hand, the fit torsion 
angles of ligand are also induced as internal ligand energy. The 
docking program will evaluate this energy to obtain the best binding 
mode. The Root-Mean-Square Deviation (RMSD) which less than 
2.0Å was scored during the docking program was run. 
RESULTS AND DISCUSSION 
Protein structure preparation 
The HIV-1 RT complex was retrieved from PDB and its structure was 
optimized using Chimera 1.8.1 program. The amino acid sequence of 
the protein is from 1 to 551 covers the full length of subunit 66 of 
HIV-1 RT. In human cell, the subunit p66 of HIV-1 RT is responsible 
to bind to RNA and causing DNA synthesis termination. HIV will start 
to build its DNA double strand from human RNA single strand 
template. Thus, subunit p66 is selected to be targeted by an 
inhibitor. The HIV-1 RT 3D structure is assesed by PROCHECK to 
analyze the allowed backbone residue torsions which quantified by 
Ramachandran plot. At the end, the 3D structure of subunit p66 is 
validated to be used as a protein model. 
Rilpivirine derivatives designed by quantitative Structure–
property relationship (QSPR) 
The drug-likeness properties of Rilpivirine derivatives were defined 
by following the Rule of Five (RO5) [18], RVN3 showed the greatest 
score among others. The octanol-water partition coefficient log P 
value of RVN1 and RVN4 are lower than five as low as Rilpivirine, 
while RVN2, RVN3, RVN5 and RVN6 have log P value greater than 5. 
The solubility of RVN1 and RVN4 compounds are greater among 
others including Rilpivirine. The topological polar surface area 
(TPSA) [19] of all compounds were also done. The TPSA score of 
RVN1 and RVN4 showed greater score compared to others. 
However, the TPSA score of all RVN compounds still below 140 Å2. 
According to Lipinski`s Rule of Violation, RVN2, RVN3, RVN5 and 
RVN6 are found one violation based on their Log P value, while 
RVN1 and RVN4 showed no violation. 
Adsorbtion, Distribution, Metabolism, Excretion and toxicity 
(ADMET) analysis 
Further analysis of Rilpivirine derivatives was continued upon their 
ADME properties. The blood brain penetration were found within 
the range of-1.2 to-2.2, which RVN4 showed the lowest value 
compared to others, while Rilpivirine showed the highest value. The 
percentage of human intestinal absorption was observed 100% to all 
compounds. The plasma protein binding percentage was obtained 
within the range 99.03-99.57%. Moreover, the hydrogen bond donor 
contribution of all compounds was in the range 2-4 bonds, while the 
acceptor hydrogen bond was found 6 bonds from all compounds. 
The toxicity predicition of Rilpivirine derivatives were assessed by 
Lazar program. The mutagenicity properties showed all compounds 
could cause mutagenic effect in longterm administration. The 
carcinogenicity tests were done in mouse showed positive results to 
all compounds, while carcinogenicity test in rat showed negative 
results upon all compound, except RVN3 which gave positive result. 
According to maximum daily dose, FDA recommended to administer 
this drug-like molecules within the range 0.0071 to 0.0113 mmol. 
Molecular docking of subunit P66 with rilpivirine derivatives 
complex 
Autodock Vina was run to predict the molecular docking of subunit 
p66 of HIV-1 RT with Rilpivirine derivatives. From docking result, 
nine conformers were found. One from out of nine was selected to be 
the best conformer with the lowest affinity energy value, associated 
to be the best interaction (data not shown). The best binding mode 
of Rilpivirine analogue conformers with subunit p66 is depicted in 
Fig.2. The binding energy value of Rilpivirine analogues are within 
the range-11.10 to-12.26 kj/mol. Amino acid residues of subunit p66 
involved in interaction with the ligand have found in binding pocket 
of subunit p66, as showed in table 4. The 3D structure of the 
complex interaction was depicted in fig. 3. 
Rilpivirine is one of NNRTIs belong to widely variant classes of 
compounds. Closer investigation showed that poly-aromatic rings of 
Rilpivirine have two nitriles in both outer side attach to benzenes. 
These nitriles have hydrophilic properties which allow them inhibit 
HIV-1 RT. Rilpivirine analogues were designed by substituting the 
nitriles with other groups. We further evaluated the designed 
analogues following Lipinski`s rule of five (RO5), which is shown in 
table 1. Lipinski`s rule of five is an important assessment to evaluate 
drug likeness; how drug-like is the substance based on its 
physicochemical properties. The aim of this evaluation is to find the 
compounds which have similar activity to the marketed drug 
molecules or clinical active candidates. The molecular properties 
important for a drug’s pharmacokinetics in living organisms should 
comply to Lipinski’s rule [20]. 
Drug-like molecules should have solubility in both water and fat, as 
an orally administering drugs need to pass through the intestinal 
pathway after it is consumed, carried in hydrophilic bloodstream 
and permeate the lipid cellular membrane to reach the target inside 
the cell. A model compound for the lipophilic cellular membrane is 
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octanol, a lipophilic hydrocarbon. Thus, the logarithm of the 
octanol/water partition coefficient, which is known as Log P, is used 
to predict the solubility of a potential oral drug. Literally, Log P value 
of drug-like molecule is between 2.0 to 5.0 [20].  
Thus, RVN1 and RVN4 have more favorable partition coefficient to 
penetrate the membrane cell compared to the other Rilpivirine 







RVN2= (E)-3-(4-((2-((4-(ethylamino) phenyl) amino) pyrimidin-4-
yl) amino)-3,5-dimethylphenyl)acrylonitrile. C23H24N6 
  
RVN3= (E)-3-(4-((2-((4-(cyclopropylamino) phenyl) amino) 










Fig. 1: Chemical structures of Rilpivirine and its analogues. Red and blue circles show the substitution of R1 and R2 groups 
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TPSA** Number of 
stereocenter** 
Lipinski`s Rule of 
Violation** 
Rilpivirine -0.06 4.89 2627.19 97.42 0 0 
RVN1 0.13 4.52 3519.75 99.65 0 0 
RVN2 0.27 5.36 1964.83 85.66 0 1 
RVN3 0.35 5.78 1676.41 85.66 0 1 
RVN4 0.10 4.90 3519.75 99.65 0 0 
RVN5 0.20 5.27 1964.83 90.24 0 1 
RVN6 0.27 5.69 1676.41 90.24 0 1 
**FAF-Drugs 
 
However, the other references showed that the allowable value of 
Rule of Five is within-0.4 to 5.6 [21-24], which means all Rilpivirine 
analogues could be acceptable in RO5. The other assessment of drug 
likeness based on the ability of drug-like molecule to efficiently 
soluble in water while the drug is transported in aqueous solution 
such as blood and intracellular fluid. RVN1 and RVN4 showed good 
solubility, this is also estimated from their sufficient number of 
hydrogen bond donors. Too many hydrogen bond donors will lead 
too low fat solubility, thus the drugs cannot penetrate the membrane 
cell to reach their target. On the other hand, the topological polar 
surface area (TPSA) of Rilpivirine analogues are less than 100 
Angstroms squared have good sum polar functional group 
contributions in the drug like molecule 3D structures. TPSA 
parameter showed very well correlation with the human intestinal 
absorption, blood brain barrier penetration and plasma protein 
binding. 
Drug-like molecules with too polar properties do not cross the BBB. 
The blood/brain partition coefficients were computed for accessing 
to the central nervous system (CNS). The predicted CNS activity was 
computed on a −2 (inactive) to+2 (active) scale and showed that all 
of the Rilpivirine analogues could be inactive in the CNS (predicted 
CNS activity<-1). At this point, Rilpivirine analogues are not 
subjected to penetrate BBB as well. The bioavailability of a 
compound depends on the processes of absorption and liver first-
pass metabolism [25]. The % human intestinal absorption depends 
on the solubility and permeability of the compound, as well as 
interactions with transporters and metabolizing enzymes in the gut 
wall. It was observed that Rilpivirine analogues were predicted to 
have the maximum human intestinal absorption which are what we 
expected. The efficiency of drug-like molecules may be affected by 
the degree to bind to the proteins within the blood plasma. It is 
known that the binding of drugs to the plasma proteins (such as 
human serum albumin, lipoprotein, glycoprotein, and globulin) will 
decrease the quantity of the drug in the normal blood circulation, 
thus, the less bound a drug is, the more efficiently it can traverse cell 
membranes or diffuse [26-28]. The percent of human intestinal 
absorption calculations revealed that all Rilpivirine analogues 
showed>98%, which indicate in majority of Rilpivirine analogues 
concentration were found in the bound fraction with plasma protein. 
It means only small amount of Rilpivirine analogues in unbound 
fraction and they are circulated freely within the blood stream to 
reach the target site then excreted.  
The assessment of drug-like molecule toxicity is also important in 
drug candidate screening. According to lazar toxicity prediction, it 
is clear that mostly designed Rilpivirine analogues have negative 
predicted toxicity level in rat while they showed positive 
carcinogenicity in mouse. However, all Rilpivirine analogues were 
found have mutagenic effect if it is administered in long-term 
therapeutic treatments. Therefore, The Federation of Drug 
Administration (FDA) has recommended the maximum daily dose 
to control drug administering effect to the body cells (table 2 and 
table 3). 
 









Blood brain barrier 
penetration 
% human intestinal 
absorption 
% Plasma protein 
binding 
Rilpivirine 2 6 366.16 -1.2 100 99.03 
RVN1 4 6 356.17 -1.5 100 99.25 
RVN2 3 6 384.21 -1.5 100 99.57 
RVN3 3 6 396.21 -1.8 100 99.61 
RVN4 4 6 356.17 -2.2 100 98.65 
RVN5 3 6 384.21 -2.0 100 98.92 
RVN6 3 6 396.21 -2.0 100 99.06 
 
Table 3: Toxicity prediction of ligand molecules are obtained from Lazar server 
Molecule Name Mutagenic Test Carcinogenicity (Mouse) Carcinogenicity (Rat) FDA recommended of max. daily dose (mmol) 
Rilpivirine Mutagen Positive Negative 0.0082 
RVN1 Mutagen Positive Negative 0.0071 
RVN2 Mutagen Positive Negative 0.0113 
RVN3 Mutagen Positive Positive 0.0076 
RVN4 Mutagen Positive Negative 0.0081 
RVN5 Mutagen Positive Negative 0.0100 
RVN6 Mutagen Positive Negative 0.0113 
 
To find the biological activities of Rilpivirine analogues, molecular 
docking was employed to investigate the favorable binding 
conformations of Rilpivirine analogues. The binding interactions 
were found in the pocket site of subunit p66 of HIV-1 RT (fig. 2). 
The interaction is found in the binding pocket is also confirmed 
from the x-ray crystal complex structure of HIV-1 RT with 
Rilpivirine. From six analogues, RVN1 showed the best affinity 
binding to HIV-1 RT compare to other analogues which also have 
the lowest binding energy-12.6 kcal/mol. This indicated that RVN 
1 has the most favorable binding to HIV-1 RT and suggested has 
the highest HIV-1 RT inhibition followed by RVN 4 with binding 
energy-11.60 kcal/mol (table 4). RVN 1 and RVN 4 were then 
chosen out of 6 analogues based on allowed Log P value less than 5 
of Lipinski’s rule of five. 
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Fig. 2: The complex of HIV-1 RT with ligand molecules in 
binding pocket of subunit p66 HIV-1 RT. Distinct colors of 
ligands show favorable conformer modes 
 
They were further analyzed to find chemical interaction with HIV-1 
RT. The interaction between HIV-1 RT and RVN 1 was stabilized by 
hydrophobic interaction in the pocket site where residues of HIV-1 
RT involved are Leu100, Lys103, Val179, Tyr181, Tyr188, Phe227, 
Trp229, and Leu234. On the other hand, the interaction is also found 
between HIV-1 RT with RVN 2 was stabilized also with hydrophobic 
interaction which residual involved of HIV-1 RT such as Leu100, 
Lys103, Val179, Tyr181, Tyr188, Phe227, Trp229, Leu234, and 
His235. These involved residues of HIV-1 RT may vary with RVN 1 
and RVN 2 due to these ligands has distinct flexible bonds which 
allow them to freely rotate in favorable orientation. It is also clear 
that the imidazole ring of His235 has significant role to stabilized the 
binding interaction with the ligands (fig. 3).  
This study serves as a chance in pursuit the great potential 
inhibitor activities against HIV-1 RT to complement the 
commercially available inhibitors of NNRTs; and as an effort to 
develop antiretroviral HAART regimens [29-32]. This 
exploration has become beneficial to gain a lead structure by 
aided-computational drug design and docking which could lead 
the precise rational drug design approach with time-consuming 
reduction and cutting high cost. This is due to the insights 
mechanism into the target binding sites which have been 
revealed unambiguously by protein X-ray crystallography 
technique. Moreover, the future design of HIV-1 inhibitor has to 
have more ability to be orally route administering besides by 
subcutaneously injection. Thus, the frequent occurrence of 




Fig. 3: Hidrophobic interaction between HIV-1 RT with ligand: a. Complex interaction between HIV-1 RT with RVN1, b. Complex 
interaction between HIV-1 RT with RVN4. Red color are the ligands and multiple color are the HIV-1 RT residues 
 





Residue involved in interaction 
Rilpivirine -12.6 Leu100, Lys103, Val179, Tyr181, Tyr188, Phe227, Trp229, Leu234, His235 
RVN1 -12.0 Leu100, Lys103, Val179, Tyr181, Tyr188, Phe227, Trp229, Leu234  
RVN2 -11.4 Trp229, Tyr188, Phe227, Leu234, His235, Val106, Pro236, Tyr318, Leu100, Lys101,Tyr181 
RVN3 -11.20 Leu100, Lys101, Lys103, Val108, Val179, Tyr181, Tyr188, Pro225, Phe227, Trp229, Leu234, His235, 
Pro236,  
RVN4 -11.60 Leu100, Lys103, Val179, Tyr181, Tyr188, Phe227, Trp229, Leu234, His235 
RVN5 -11.10 Leu100, Lys103, Val179, Tyr181, Tyr188, Pro225, Phe227, Trp229, Leu234, His235  
RVN6 -11.10 Leu100, Lys101, Lys103, Val106, Val179, Tyr188, Phe227, Trp229, Leu234, His235 
 
CONCLUSION 
The designed drug-like molecules had been successfully evaluated 
computationally on the basis of QSPR and pharmacophore study 
which would be more effective and potent in pre-clinical and clinical 
trials compares to the prototype molecules. The binding 
conformations of Rilpivirine analogues inside the non nucleoside 
binding pocket of HIV-1 RT were determined by docking approach 
and their binding affinities have been predicted. The binding mode 
of the inhibitors clearly shows a common mode of interaction upon 
binding to the HIV-1 RT allosteric site. This study would need 
further evaluation in wet experiments including in-vitro and in-vivo 
studies to convince the high potency of Rilpivirine analogues in 
inhibiting HIV-1 RT. 
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